Akzo Nobel N.V .(NasdaqNM: AKZOY) Akzo Nobel N.V. operates as a technology-based company, which provides healthcare products, coatings, and chemicals to the customers worldwide. Its Pharma segment engages in the research, development, manufacture, sale, and service of human and animal healthcare products, including prescription medicines, veterinary products, and active pharmaceutical ingredients. The company's Coating segment produces paints, finishes, stains, and synthetic resins for industrial applications, professional painters, and the do-it-yourself sector. Its product areas include decorative/architectural paint, car refinishes, liquid and powder coatings for industrial use, marine and yacht coatings, protective coatings, aerospace coatings, and industrial and consumer adhesives. Akzo Nobel's Chemicals segment is a mix of specialty, functional, and commodity chemicals based on the positions in certain segments of the chemical industry. Its products consist of pulp bleaching chemicals; speciality resins; surfactants and fatty acids; water treatment chemicals; chlorine and caustic soda; polymerization catalysts; and salt for electrolysis, other chemical industries, food applications, and consumer use. The company operates primarily in Europe, North America, Latin America, Asia, the Middle East, and Africa. The company was founded 1911 and is headquartered in Arnhem, the Netherlands.
Alexion Pharmaceuticals, Inc . (Nasdaq: ALXN) is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders.
Alfacell Corporation (Nasdaq: ACEL) is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other diseases, using its ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I/II trial in Non-Small Cell Lung Cancer (NSCLC).
Align Technology, Inc . (Nasdaq: ALGN) manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal or ceramic brackets and wires, Invisalign significantly reduces the aesthetic and other limitations associated with braces. Invisalign is appropriate for treating adults and older teens. Align Technology was founded in March 1997 and received FDA clearance to market Invisalign in 1998.
Amgen (AMGN) is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
Applied DNA Sciences, Inc. (OTCBB: APDN), a development stage company, provides DNA-embedded biotechnology security products that protect corporate and intellectual property from counterfeiting, fraud, piracy, product diversion, and unauthorized intrusion. The company offers DNA security systems, supply-chain management systems, and anti-counterfeit solutions. It offers various DNA products, including markers, anti-counterfeit inks, labels, and chips. The company markets and sells its products primarily to corporations and government agencies principally in the United States and Europe. Applied DNA Sciences was incorporated in 2002 and is headquartered in Los Angeles, California.
Bio-Bridge Science, Inc (OTCBB: BGES) and its subsidiaries are engaged in the business of developing and commercializing biological products particularly for HIV treatment and prevention. They develop HIV vaccines for both preventive and therapeutic purposes. They intend to conduct clinical trials for such potential products in China, taking advantage of the low cost of conducting such tests in China and China's “Green Mile” drug approval process for anti-AIDS drugs. They are in the process of building a laboratory facility in Beijing, China, which we intend to make in compliance with Good Manufacturing Practice regulation. The facility is intended to be used to conduct the clinical trials of HIV vaccine product.
BIO-key (OTC: BKYI) develops and delivers advanced identification solutions and information services to law enforcement departments, public safety agencies, government and private sector customers.
Bio-Matrix Scientific Group, Inc. (OTC.PK: BMXG) is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems.
Biogen, Inc. (BGEN)is the world's oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients' lives around the world through its global marketing capabilities.
